Your browser doesn't support javascript.
loading
Contribution of different relapse phenotypes to disability in multiple sclerosis.
Stewart, Tamasine; Spelman, Tim; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Izquierdo, Guillermo; Duquette, Pierre; Girard, Marc; Prat, Alexandre; Lugaresi, Alessandra; Grand'Maison, Francois; Grammond, Pierre; Sola, Patrizia; Shaygannejad, Vahid; Hupperts, Raymond; Alroughani, Raed; Oreja-Guevara, Celia; Pucci, Eugenio; Boz, Cavit; Lechner-Scott, Jeannette; Bergamaschi, Roberto; Van Pesch, Vincent; Iuliano, Gerardo; Ramo, Cristina; Taylor, Bruce; Slee, Mark; Spitaleri, Daniele; Granella, Franco; Verheul, Freek; McCombe, Pamela; Hodgkinson, Suzanne; Amato, Maria Pia; Vucic, Steve; Gray, Orla; Cristiano, Edgardo; Barnett, Michael; Sanchez Menoyo, Jose Luis; van Munster, Erik; Saladino, Maria Laura; Olascoaga, Javier; Prevost, Julie; Deri, Norma; Shaw, Cameron; Singhal, Bhim; Moore, Fraser; Rozsa, Csilla; Shuey, Neil; Skibina, Olga; Kister, Ilya; Petkovska-Boskova, Tatjana.
Afiliación
  • Stewart T; Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia.
  • Spelman T; Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia/Department of Neurology, Melbourne Brain Centre at Royal Melbourne Hospital, Parkville, VIC, Australia.
  • Havrdova E; Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Prague, Czech Republic.
  • Horakova D; Department of Neurology and Center of Clinical Neuroscience, General University Hospital and Charles University in Prague, Prague, Czech Republic.
  • Trojano M; Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari Aldo Moro, Bari, Italy.
  • Izquierdo G; Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Duquette P; Hôpital Notre Dame, CHUM and Université de Montréal, Montreal, QC, Canada.
  • Girard M; Hôpital Notre Dame, CHUM and Université de Montréal, Montreal, QC, Canada.
  • Prat A; Hôpital Notre Dame, CHUM and Université de Montréal, Montreal, QC, Canada.
  • Lugaresi A; MS Centre, Department of Neuroscience, Imaging and Clinical Sciences, 'G. d'Annunzio' University of Chieti-Pescara, Chieti, Italy.
  • Grand'Maison F; Neuro Rive-Sud, Hôpital Charles LeMoyne, Greenfield Park, QC, Canada.
  • Grammond P; Hôtel-Dieu de Lévis, Levis, QC, Canada.
  • Sola P; Neurology Unit, Department of Neuroscience, Nuovo Ospedale Civile S. Agostino-Estense, Modena, Italy.
  • Shaygannejad V; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  • Hupperts R; Zuyderland Ziekenhuis, Sittard, The Netherlands.
  • Alroughani R; Department of Neurology, Amiri Hospital, Kuwait City, Kuwait.
  • Oreja-Guevara C; University Hospital San Carlos, El Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.
  • Pucci E; Neurology Unit, ASUR Marche AV3, Macerata, Italy.
  • Boz C; Karadeniz Technical University, Trabzon, Turkey.
  • Lechner-Scott J; Hunter Medical Research Institute, The University of Newcastle Australia, Callaghan, NSW, Australia.
  • Bergamaschi R; C. Mondino National Neurological Institute, Pavia, Italy.
  • Van Pesch V; Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Iuliano G; Ospedali Riuniti di Salerno, Salerno, Italy.
  • Ramo C; Hospital Germans Trias i Pujol, Badalona, Spain.
  • Taylor B; Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
  • Slee M; Flinders University and Medical Centre, Adelaide, SA, Australia.
  • Spitaleri D; AORN San Giuseppe Moscati, Avellino, Italy.
  • Granella F; University of Parma, Parma, Italy.
  • Verheul F; Groene Hart Ziekenhuis, Gouda, The Netherlands.
  • McCombe P; Centre for Clinical Research, The University of Queensland Australia, Brisbane, QLD, Australia.
  • Hodgkinson S; Departments of Nephrology and Neurology, Liverpool Hospital, Liverpool, NSW, Australia.
  • Amato MP; Section of Neurosciences, NEUROFARBA, University of Florence, Florence, Italy.
  • Vucic S; Westmead Hospital, Sydney, NSW, Australia.
  • Gray O; Craigavon Area Hospital, Portadown, UK.
  • Cristiano E; Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Barnett M; Brain and Mind Centre, Camperdown, NSW, Australia.
  • Sanchez Menoyo JL; Department of Neurology, Hospital de Galdakao-Usansolo, Galdakao, Spain.
  • van Munster E; Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands.
  • Saladino ML; Ineba, Buenos Aires, Argentina.
  • Olascoaga J; Department of Neurology, Donostia University Hospital, San Sebastian, Spain.
  • Prevost J; Centre Intégré de Santé et de Services Sociaux des Laurentides, Saint-Jerome, QC, Canada.
  • Deri N; Hospital Fernandez, Buenos Aires, Argentina.
  • Shaw C; Geelong Hospital, Geelong, VIC, Australia.
  • Singhal B; Bombay Hospital Institute of Medical Sciences, Mumbai, India.
  • Moore F; Jewish General Hospital, Montreal, QC, Canada.
  • Rozsa C; Jahn Ferenc Teaching Hospital, Budapest, Hungary.
  • Shuey N; St Vincent's Hospital, Melbourne, Melbourne, VIC, Australia.
  • Skibina O; The Alfred Hospital, Melbourne, VIC, Australia.
  • Kister I; Department of Neurology, NYU School of Medicine, New York, NY, USA.
  • Petkovska-Boskova T; Clinical Neurology Clinical Center, Skopje, Macedonia.
Mult Scler ; 23(2): 266-276, 2017 Feb.
Article en En | MEDLINE | ID: mdl-27055805
ABSTRACT

OBJECTIVE:

This study evaluated the effect of relapse phenotype on disability accumulation in multiple sclerosis.

METHODS:

Analysis of prospectively collected data was conducted in 19,504 patients with relapse-onset multiple sclerosis and minimum 1-year prospective follow-up from the MSBase cohort study. Multivariable linear regression models assessed associations between relapse incidence, phenotype and changes in disability (quantified with Expanded Disability Status Scale and its Functional System scores). Sensitivity analyses were conducted.

RESULTS:

In 34,858 relapses recorded during 136,462 patient-years (median follow-up 5.9 years), higher relapse incidence was associated with greater disability accumulation (ß = 0.16, p < 0.001). Relapses of all phenotypes promoted disability accumulation, with the most pronounced increase associated with pyramidal (ß = 0.27 (0.25-0.29)), cerebellar (ß = 0.35 (0.30-0.39)) and bowel/bladder (ß = 0.42 (0.35-0.49)) phenotypes (mean (95% confidence interval)). Higher incidence of each relapse phenotype was associated with an increase in disability in the corresponding neurological domain, as well as anatomically related domains.

CONCLUSION:

Relapses are associated with accumulation of neurological disability. Relapses in pyramidal, cerebellar and bowel/bladder systems have the greatest association with disability change. Therefore, prevention of these relapses is an important objective of disease-modifying therapy. The differential impact of relapse phenotypes on disability outcomes could influence management of treatment failure in multiple sclerosis.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Recurrencia / Interferón beta / Personas con Discapacidad / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Recurrencia / Interferón beta / Personas con Discapacidad / Esclerosis Múltiple Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2017 Tipo del documento: Article País de afiliación: Australia